Clinical trial
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
NCT00355641 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00355641 |
|---|---|
| Title | Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome |
| Official title | A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Ropinirole Extended Release (XR) |
| Enrollment | 450 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jul 24, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: